Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Inventory (2022 - 2025)

Axsome Therapeutics' Change in Inventory history spans 4 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 222.41% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $10.7 million, up 1532.8%, while the annual FY2025 figure was $10.7 million, 1532.8% up from the prior year.
  • Change in Inventory for Q4 2025 was $3.6 million at Axsome Therapeutics, down from $5.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $5.0 million in Q3 2025 and bottomed at -$1.7 million in Q3 2023.
  • The 4-year median for Change in Inventory is $1.2 million (2023), against an average of $1.4 million.
  • The largest annual shift saw Change in Inventory tumbled 681.82% in 2023 before it surged 487.73% in 2025.
  • A 4-year view of Change in Inventory shows it stood at $1.3 million in 2022, then skyrocketed by 269.74% to $4.9 million in 2023, then crashed by 76.9% to $1.1 million in 2024, then soared by 222.41% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Change in Inventory are $3.6 million (Q4 2025), $5.0 million (Q3 2025), and $1.8 million (Q2 2025).